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Abstract
We aggregated coding variant data for 81,412 type 2 diabetes cases and 370,832 controls of 
diverse ancestry, identifying 40 coding variant association signals (p<2.2×10−7): of these, 16 map 
outside known risk loci. We make two important observations. First, only five of these signals are 
driven by low-frequency variants: even for these, effect sizes are modest (odds ratio ≤1.29). 
Second, when we used large-scale genome-wide association data to fine-map the associated 
variants in their regional context, accounting for the global enrichment of complex trait 
associations in coding sequence, compelling evidence for coding variant causality was obtained 
for only 16 signals. At 13 others, the associated coding variants clearly represent “false leads” with 
potential to generate erroneous mechanistic inference. Coding variant associations offer a direct 
route to biological insight for complex diseases and identification of validated therapeutic targets: 
however, appropriate mechanistic inference requires careful specification of their causal 
contribution to disease predisposition.
Genome-wide association studies (GWAS) have identified thousands of association signals 
influencing multifactorial traits such as type 2 diabetes (T2D) and obesity1–7. Most of these 
associations involve common variants that map to non-coding sequence, and identification 
of their cognate effector transcripts has proved challenging. Identification of coding variants 
causally implicated in trait predisposition offers a more direct route from association signal 
to biological inference.
The exome occupies 1.5% of overall genome sequence, but for many common diseases, 
coding variants make a disproportionate contribution to trait heritability8,9. This enrichment 
indicates that coding variant association signals have an enhanced probability of being 
causal when compared to those involving an otherwise equivalent non-coding variant. This 
does not, however, guarantee that all coding variant associations are causal. Alleles driving 
common-variant (minor allele frequency [MAF] ≥5%) GWAS signals typically reside on 
extended risk haplotypes that, owing to linkage disequilibrium (LD), incorporate many 
common variants10,11. Consequently, the presence of a coding allele on the risk haplotype 
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does not constitute sufficient evidence that it represents the causal variant at the locus, or 
that the gene within which it lies is mediating the association signal. Since much coding 
variant discovery has proceeded through exome-specific analyses (either exome-array 
genotyping or exome sequencing), researchers have often been poorly-placed to position 
coding variant associations in the context of regional genetic variation. It is unclear how 
often this may have led to incorrect assumptions regarding their causal role.
In our recent study of T2D predisposition12, we surveyed the exomes of 34,809 T2D cases 
and 57,985 controls, of predominantly European descent, and identified 13 distinct coding 
variant associations reaching genome-wide significance. Twelve of these associations 
involved common variants, but the data hinted at a substantial pool of lower-frequency 
coding variants of moderate impact, potentially amenable to detection in larger samples. We 
also reported that, whilst many of these signals fell within common variant loci previously 
identified by GWAS, it was far from trivial to determine, using available data, whether those 
coding variants were causal or ‘hitchhiking’ on risk haplotypes.
Here, we report analyses that address these two issues. First, we extend the scope of our 
exome-array genotyping to include data from 81,412 T2D cases and 370,832 controls of 
diverse ancestry, substantially increasing power to detect coding variant associations across 
the allele-frequency spectrum. Second, to understand the extent to which identification of 
coding variant associations provides a reliable guide to causal mechanisms, we undertake 
high-resolution fine-mapping of identified coding variant association signals in 50,160 T2D 
cases and 465,272 controls of European ancestry with genome-wide genotyping data.
RESULTS
Discovery study overview
First, we set out to discover coding variant association signals by aggregating T2D 
association summary statistics in up to 452,244 individuals (effective sample size 228,825) 
across five ancestry groups, performing both European-specific (EUR) and trans-ethnic (TE) 
meta-analyses (Supplementary Tables 1 and 2). Analysis was restricted to the 247,470 
variants represented on the exome-array. Genotypes were assembled from: (a) 58,425 cases 
and 188,032 controls genotyped with the exome-array; (b) 14,608 cases and 174,322 
controls from UK Biobank and GERA (Resource for Genetic Epidemiology on Adult Health 
and Aging) genotyped with GWAS arrays enriched for exome content and/or coverage of 
low-frequency variation across ethnic groups13,14; and (c) 8,379 cases and 8,478 controls 
with whole-exome sequence from GoT2D/T2D-GENES12 and SIGMA15 studies. Overall, 
this represented a 3-fold increase in effective sample size over our previous study of T2D 
predisposition within coding sequence12. To deconvolute the impact of obesity on T2D-
associated variants, association analyses were conducted with and without body mass index 
(BMI) adjustment.
We considered p<2.2×10−7 as significant for protein truncating variants (PTVs) and 
moderate impact coding variants (including missense, in-frame indel and splice region 
variants) based on a weighted Bonferroni correction that accounts for the observed 
enrichment in complex trait association signals across sequence annotation16. This threshold 
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matches those obtained through other approaches such as simple Bonferroni correction for 
the number of coding variants on the exome-array (Methods). Compared to our previous 
study12, the expanded sample size substantially increased power to detect association for 
common variants of modest effect (e.g. from 14.4% to 97.9% for a variant with 20% MAF 
and odds ratio [OR]=1.05) and lower-frequency variants with larger effects (e.g. from 11.8% 
to 97.5% for a variant with 1% MAF and OR=1.20) assuming homogenous allelic effects 
across ancestry groups (Methods).
Insights into coding variant association signals underlying T2D susceptibility
We detected significant associations at 69 coding variants under an additive genetic model 
(either in BMI unadjusted or adjusted analysis), mapping to 38 loci (Supplementary Fig. 1, 
Supplementary Table 3). We observed minimal evidence of heterogeneity in allelic OR 
between ancestry groups (Supplementary Table 3), and no compelling evidence for non-
additive allelic effects (Supplementary Fig. 2, Supplementary Table 4). Reciprocal 
conditional analyses (Methods) indicated that the 69 coding variants represented 40 distinct 
association signals (conditional p<2.2×10−7) across the 38 loci, with two distinct signals 
each at HNF1A and RREB1 (Supplementary Table 5). These 40 signals included the 13 
associations reported in our earlier publication12, each featuring more significant 
associations in this expanded meta-analysis (Supplementary Table 6). Twenty-five of the 40 
signals were significant in both EUR and TE analyses. Of the other 15, three (PLCB3, 
C17orf58, and ZHX3) were significant in EUR, and all reached pTE<6.8×10−6 in the TE 
analysis: for PLCB3 and ZHX3, risk allele frequencies were substantially lower outside 
European descent populations. Twelve loci (Supplementary Table 3) were significant in TE 
alone, but for these (except PAX4 which is East Asian specific), the evidence for association 
was proportionate in the smaller EUR component (pEUR<8.4×10−5).
Sixteen of the 40 distinct association signals mapped outside regions previously implicated 
in T2D susceptibility (Methods, Table 1). These included missense variant signals in POC5 
(p.His36Arg, rs2307111, pTE=1.6×10−15), PNPLA3 (p.Ile148Met, rs738409, pTE BMI-
adjusted=2.8×10−11), and ZZEF1 (p.Ile2014Val, rs781831, pTE=8.3×10−11).
In addition to the 69 coding variant signals, we detected significant (p<5×10−8) and novel 
T2D-associations for 20 non-coding variants (at 15 loci) that were also assayed on the 
exome-array (Supplementary Table 7). Three of these (POC5, LPL, and BPTF) overlap with 
novel coding signals reported here.
Contribution of low-frequency and rare coding variation to T2D susceptibility
Despite increased power and good coverage of low-frequency variants on the exome-array12, 
35 of the 40 distinct coding variant association signals were common, with modest effects 
(allelic ORs 1.02–1.36) (Supplementary Fig. 3, Supplementary Table 3). The five signals 
attributable to lower-frequency variants were also of modest effect (allelic ORs 1.09–1.29) 
(Supplementary Fig. 3). Two of the lower-frequency variant signals were novel, and in both, 
the minor allele was protective against T2D: FAM63A p.Tyr95Asn (rs140386498, 
MAF=1.2%, OR= 0.82 [0.77–0.88], pEUR=5.8×10−8) and ANKH p.Arg187Gln 
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(rs146886108, MAF=0.4%, OR=0.78 [0.69–0.87], pEUR=2.0×10−7). Both variants were very 
rare or monomorphic in non-European descent individuals.
In Fuchsberger et al.12, we highlighted a set of 100 low-frequency coding variants with 
allelic ORs between 1.10 and 2.66, which despite relatively large estimates for liability-scale 
variance explained, had not reached significance. In this expanded analysis, only five of 
these variants, including the two novel associations at FAM63A p.Tyr95Asn and ANKH 
p.Arg187Gln, attained significance. More precise effect-size estimation in the larger sample 
size indicates that OR estimates in the earlier study were subject to a substantial upwards 
bias (Supplementary Fig. 3).
To detect additional rare variant association signals, we performed gene-based analyses 
(burden and SKAT17) using previously-defined “strict” and “broad” masks, filtered for 
annotation and MAF12,18 (Methods). We identified gene-based associations with T2D 
susceptibility (p<2.5×10−6, Bonferroni correction for 20,000 genes) for FAM63A (10 
variants, combined MAF=1.9%, pEUR=3.1×10−9) and PAM (17 variants, combined 
MAF=4.7%, pTE=8.2×10−9). On conditional analysis (Supplementary Table 8), the gene-
based signal at FAM63A was entirely attributable to the low-frequency p.Tyr95Asn allele 
described earlier (conditional p=0.26EUR). The gene-based signal for PAM was also driven 
by a single low-frequency variant (p.Asp563Gly; conditional pTE=0.15). A second, 
previously-described, low-frequency variant, PAM p.Ser539Trp19, is not represented on the 
exome-array, and did not contribute to these analyses.
Fine-mapping of coding variant association signals with T2D susceptibility
These analyses identified 40 distinct coding variant associations with T2D, but this 
information is not sufficient to determine that these variants are causal for disease. To assess 
the role of these coding variants given regional genetic variation, we fine-mapped these 
association signals using a meta-analysis of 50,160 T2D cases and 465,272 controls 
(European-descent only; partially overlapping with the discovery samples), which we 
aggregated from 24 GWAS. Each component GWAS was imputed using appropriate high-
density reference panels (for most, the Haplotype Reference Consortium20; Methods, 
Supplementary Table 9). Before fine-mapping, distinct association signals were delineated 
using approximate conditional analyses (Methods, Supplementary Table 5). We included 37 
of the 40 identified coding variants in this fine-mapping analysis, excluding three (those at 
the MHC, PAX4, and ZHX3) that were, for various reasons (see Methods), not amenable to 
fine-mapping in the GWAS data.
For each of these 37 signals, we first constructed “functionally-unweighted” credible variant 
sets, which collectively account for 99% of the posterior probability of association (PPA), 
based exclusively on the meta-analysis summary statistics21 (Methods, Supplementary 
Table 10). For each signal, we calculated the proportion of PPA attributable to coding 
variants (missense, in-frame indel, and splice region variants; Figure 1, Supplementary Fig. 
4 and 5). There were only two signals at which coding variants accounted for ≥80% of PPA: 
HNF4A p.Thr139Ile (rs1800961, PPA>0.999) and RREB1 p. Asp1171Asn (rs9379084, 
PPA=0.920). However, at other signals, including those for GCKR p.Pro446Leu and 
SLC30A8 p.Arg276Trp, for which robust empirical evidence has established a causal 
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role22,23, genetic support for coding variant causation was weak. This is because coding 
variants were typically in high LD (r2>0.9) with large numbers of non-coding variants, such 
that the PPA was distributed across many sites with broadly equivalent evidence for 
association.
These functionally-unweighted sets are based on genetic fine-mapping data alone, and do 
not account for the disproportionate representation of coding variants amongst GWAS 
associations for complex traits8,9. To accommodate this information, we extended the fine-
mapping analyses by incorporating an “annotation-informed prior” model of causality. We 
derived priors from estimates of the enrichment of association signals by sequence 
annotation from analyses conducted by deCODE across 96 quantitative and 123 binary 
phenotypes16 (Methods). This model “boosts” the prior, and hence the posterior 
probabilities (we use ‘aiPPA’ to denote annotation-informed PPAs) of coding variants. It also 
takes account (in a tissue-non-specific manner) of the GWAS enrichment of variants within 
enhancer elements (as assayed through DNase I hypersensitivity) when compared to non-
coding variants mapping elsewhere. The annotation-informed model generated smaller 99% 
credible sets across most signals, corresponding to fine-mapping at higher resolution 
(Supplementary Table 10). As expected, the contribution of coding variants was increased 
under the annotation-informed model. At these 37 association signals, we distinguished 
three broad patterns of causal relationships between coding variants and T2D risk.
Group 1: T2D association signal is driven by coding variants—At 16 of the 37 
distinct signals, coding variation accounted for >80% of the aiPPA (Fig. 1, Table 2, 
Supplementary Table 10). This was attributable to a single coding variant at 12 signals and 
multiple coding variants at four. Reassuringly, group 1 signals confirmed coding variant 
causation for several loci (GCKR, PAM, SLC30A8, KCNJ11-ABCC8) at which functional 
studies have established strong mechanistic links to T2D pathogenesis (Table 2). T2D 
association signals at the 12 remaining signals (Fig. 1, Supplementary Table 10) had not 
previously been shown to be driven by coding variation, but our fine-mapping analyses 
pointed to causal coding variants with high aiPPA values: these included HNF4A, RREB1 
(p. Asp1171Asn), ANKH, WSCD2, POC5, TM6SF2, HNF1A (p.Ala146Val; p.Ile75Leu), 
GIPR, LPL, PLCB3, and PNPLA3 (Table 2). At several of these, independent evidence 
corroborates the causal role of the genes harbouring the associated coding variants. For 
example, rare coding mutations at HNF1A and HNF4A are causal for monogenic, early-
onset forms of diabetes24; and at TM6SF2 and PNPLA3, the associated coding variants are 
implicated in the development of non-alcoholic fatty liver disease (NAFLD)25,26.
The use of priors to capture the enrichment of coding variants seems a reasonable model, 
genome-wide. However, at any given locus, strong priors (especially for PTVs) might 
elevate to apparent causality, variants that would have been excluded from a causal role on 
the basis of genetic fine-mapping alone. Comparison of the annotation-informed and 
functionally-unweighted credible sets for group 1 signals indicated that this scenario was 
unlikely. For 11 of the 16 (GCKR, PAM, KCNJ11-ABCC8, HNF4A, RREB1 
[p.Asp1171Asn], ANKH, POC5, TM6SF2, HNF1A [p.Ala146Val], PLCB3, PNPLA3), the 
coding variant had the highest PPA in the fine-mapping analysis (Table 2) even under the 
functionally-unweighted model. At SLC30A8, WSCD2, and GIPR, the coding variants had 
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similar PPAs to the lead non-coding SNPs under the functionally-unweighted prior (Table 
2). At these 14 signals therefore, coding variants have either greater or equivalent PPA to the 
best flanking non-coding SNPs under the functionally-unweighted model, but receive a 
boost in PPA after incorporating the annotation weights.
The situation is less clear at LPL. Here, fine-mapping resolution is poor under the 
functionally-unweighted prior, and the coding variant sits on an extended haplotype in 
strong LD with non-coding variants, some with higher PPA, such as rs74855321 
(PPA=0.048) (compared to LPL p.Ser474* [rs328, PPA=0.023]). However, LPL p.Ser474* 
is annotated as a PTV, and benefits from a substantially-increased prior that boosts its 
annotation-informed ranking (Table 2). Ultimately, decisions regarding the causal role of any 
such variant must rest on the amalgamation of evidence from diverse sources including 
detailed functional evaluation of the coding variants, and of other variants with which they 
are in LD.
Group 2: T2D association signals are not attributable to coding variants—At 
13 of the 37 distinct signals, coding variation accounted for <20% of the PPA, even after 
applying the annotation-informed prior model. These signals are likely to be driven by local 
non-coding variation and mediated through regulatory mechanisms. Five of these signals 
(TPCN2, MLX, ZZEF1, C17orf58, and CEP68) represent novel T2D-association signals 
identified in the exome-focused analysis. Given the exome-array discoveries, it would have 
been natural to consider the named genes at these, and other loci in this group, as candidates 
for mediation of their respective association signals. However, the fine-mapping analyses 
indicate that these coding variants do not provide useful mechanistic inference given low 
aiPPA (Fig. 1, Table 2).
The coding variant association at the CENTD2 (ARAP1) locus is a case-in-point. The 
association with the p.Gln802Glu variant in ARAP1 (rs56200889, pTE=4.8×10−8 but 
aiPPA<0.001) is seen in the fine-mapping analysis to be secondary to a substantially stronger 
non-coding association signal involving a cluster of variants including rs11603334 
(pTE=9.5×10−18, aiPPA=0.0692) and rs1552224 (pTE=2.5×10−17, aiPPA=0.0941). The 
identity of the effector transcript at this locus has been the subject of detailed investigation, 
and some early studies used islet expression data to promote ARAP127. However, a more 
recent study integrating human islet genomics and murine gene knockout data establishes 
STARD10 as the gene mediating the GWAS signal, consistent with the reassignment of the 
ARAP1 coding variant association as irrelevant to causal inference28.
Whilst, at these loci, the coding variant associations represent “false leads”, this does not 
necessarily exclude the genes concerned from a causal role. At WFS1 for example, coding 
variants too rare to be visible to the array-based analyses we performed, and statistically 
independent of the common p.Val333Ile variant we detected, cause an early-onset form of 
diabetes that renders WFS1 the strongest local candidate for T2D predisposition.
Group 3: Fine-mapping data consistent with partial role for coding variants—
At eight of the 37 distinct signals, the aiPPA attributable to coding variation lay between 
20% and 80%. At these signals, the evidence is consistent with “partial” contributions from 
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coding variants, although the precise inference is likely to be locus-specific, dependent on 
subtle variations in LD, imputation accuracy, and the extent to which global priors 
accurately represent the functional impact of the specific variants concerned.
This group includes PPARG for which independent evidence corroborates the causal role of 
this specific effector transcript with respect to T2D-risk. PPARG encodes the target of 
antidiabetic thiazolidinedione drugs and harbours very rare coding variants causal for 
lipodystrophy and insulin resistance, conditions highly-relevant to T2D. The common 
variant association signal at this locus has generally been attributed to the p.Pro12Ala coding 
variant (rs1801282) although empirical evidence that this variant influences PPARG 
function is scant29–31. In the functionally-unweighted analysis, p.Pro12Ala had an 
unimpressive PPA (0.0238); after including annotation-informed priors, the same variant 
emerged with the highest aiPPA (0.410), although the 99% credible set included 19 non-
coding variants, spanning 67kb (Supplementary Table 10). These credible set variants 
included rs4684847 (aiPPA=0.0089), at which the T2D-associated allele has been reported to 
impact PPARG2 expression and insulin sensitivity by altering binding of the homeobox 
transcription factor PRRX132. These data are consistent with a model whereby regulatory 
variants contribute to altered PPARG activity in combination with, or potentially to the 
exclusion of, p.Pro12Ala. Future improvements in functional annotation for regulatory 
variants (gathered from relevant tissues and cell types) should provide increasingly granular 
priors that allow fine-tuned assignment of causality at loci such as this.
Functional impact of coding alleles
In other contexts, the functional impact of coding alleles is correlated with: (i) variant-
specific features, including measures of conservation and predicted impact on protein 
structure; and (ii) gene-specific features such as extreme selective constraints as quantified 
by the intolerance to functional variation33. To determine whether similar measures could 
capture information pertinent to T2D causation, we compared coding variants falling into 
the different fine-mapping groups for a variety of measures including MAF, Combined 
Annotation Dependent Depletion (CADD) score34, and loss-of-function (LoF)-intolerance 
metric, pLI33 (Methods, Fig. 2). Variants from group 1 had significantly higher CADD-
scores than those in group 2 (Kolmogorov-Smirnov p=0.0031). Except for the variants at 
KCNJ11-ABCC8 and GCKR, all group 1 coding variants considered likely to be driving 
T2D association signals had CADD-score ≥20. On this basis, we predict that the East-Asian 
specific coding variant at PAX4, for which the fine-mapping data were not informative, is 
also likely causal for T2D.
T2D loci and physiological classification
The development of T2D involves dysfunction of multiple mechanisms. Systematic analysis 
of the physiological effects of known T2D-risk alleles has improved understanding of the 
mechanisms through which they exert their primary impact on disease risk35. We obtained 
association summary statistics for diverse metabolic traits (and other outcomes) for 94 T2D-
associated index variants. These 94 were restricted to sites represented on the exome-array 
and included the 40 coding signals plus 54 distinct non-coding signals (12 novel and 42 
previously-reported non-coding GWAS lead SNPs). We applied clustering techniques 
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(Methods) to generate multi-trait association patterns, allocating 71 of the 94 loci to one of 
three main physiological categories (Supplementary Figs. 6, Supplementary Table 11). The 
first category, comprising nine T2D-risk loci with strong BMI and dyslipidemia 
associations, included three of the novel coding signals: PNPLA3, POC5 and BPTF. The 
T2D associations at both POC5 and BPTF were substantially attenuated (>2-fold decrease in 
−log10p) after adjusting for BMI (Table 1, Supplementary Table 3, Supplementary Fig. 7), 
indicating that their impact on T2D-risk is likely mediated by a primary effect on adiposity. 
PNPLA3 and POC5 are established NAFLD25 and BMI6 loci, respectively. The second 
category featured 39 loci at which multi-trait profiles indicated a primary effect on insulin 
secretion. This set included four of the novel coding variant signals (ANKH, ZZEF1, 
TTLL6, ZHX3). The third category encompassed 23 loci with primary effects on insulin 
action, including signals at the KIF9, PLCB3, CEP68, TPCN2, FAM63A, and PIM3 loci. 
For most variants in this category, the T2D-risk allele was associated with lower BMI, and 
T2D association signals were more pronounced after adjustment for BMI. At a subset of 
these loci, including KIF9 and PLCB3, T2D-risk alleles were associated with higher waist-
hip ratio and lower body fat percentage, indicating that the mechanism of action likely 
reflects limitations in storage capacity of peripheral adipose tissue36.
DISCUSSION
The present study adds to mounting evidence constraining the contribution of lower-
frequency variants to T2D-risk. Although the exome-array interrogates only a subset of the 
universe of coding variants, it captures the majority of low-frequency coding variants in 
European populations. The substantial increase in sample size in the present study over our 
previous effort12 (effective sample sizes of 228,825 and 82,758, respectively), provides more 
robust evaluation of the effect size distribution in this low-frequency variant range, and 
indicates that previous analyses are likely, if anything, to have overestimated the contribution 
of low-frequency variants to T2D-risk.
The present study is less informative regarding rare variants. These are sparsely captured on 
the exome-array. In addition, the combination of greater regional diversity in rare allele 
distribution and the enormous sample sizes required to detect rare variant associations 
(likely to require meta-analysis of data from diverse populations) acts against their 
identification. Our complementary genome and exome sequence analyses have thus far 
failed to register strong evidence for a substantial rare variant component to T2D-risk12. It is 
therefore highly unlikely that rare variants missed in our analyses are causal for any of the 
common or low-frequency variant associations we have detected and fine-mapped. On the 
other hand, it is probable that rare coding alleles, with associations that are distinct from the 
common variant signals we have examined and detected only through sequence based 
analyses, will provide additional clues to the most likely effector transcripts at some of these 
signals (WFS1 provides one such example).
Once a coding variant association is detected, it is natural to assume a causal connection 
between that variant, the gene in which it sits, and the phenotype of interest. Whilst such 
assignments may be robust for many rare protein-truncating alleles, we demonstrate that this 
implicit assumption is often inaccurate, particularly for associations attributable to common, 
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missense variants. A third of the coding variant associations we detected were, when 
assessed in the context of regional LD, highly unlikely to be causal. At these loci, the genes 
within which they reside are consequently deprived of their implied connection to disease 
risk, and attention redirected towards nearby non-coding variants and their impact on 
regional gene expression. As a group, coding variants we assign as causal are predicted to 
have a more deleterious impact on gene function than those that we exonerate, but, as in 
other settings, coding annotation methods lack both sensitivity and specificity. It is worth 
emphasising that empirical evidence that the associated coding allele is “functional” (i.e. can 
be shown to influence cognate gene function in some experimental assay) provides limited 
reassurance that the coding variant is responsible for the T2D association, unless that 
specific perturbation of gene function can itself be plausibly linked to the disease phenotype.
Our fine-mapping analyses make use of the observation that coding variants are globally 
enriched across GWAS signals8,9,16 with greater prior probability of causality assigned to 
those with more severe impact on biological function. We assigned diminished priors to non-
coding variants, with lowest support for those mapping outside of DNase I hypersensitive 
sites. The extent to which our findings corroborate previous assignments of causality (often 
substantiated by detailed, disease-appropriate functional assessment and other orthogonal 
evidence) suggests that even these sparse annotations provide valuable information to guide 
target validation. Nevertheless, there are inevitable limits to the extrapolation of these 
‘broad-brush’ genome-wide enrichments to individual loci: improvements in functional 
annotation for both coding and regulatory variants, particularly when gathered from trait-
relevant tissues and cell types, should provide more granular, trait-specific priors to fine-tune 
assignment of causality within associated regions. These will motivate target validation 
efforts that benefit from synthesis of both coding and regulatory mechanisms of gene 
perturbation. It also needs to be acknowledged that, without whole genome sequencing data 
on sample sizes comparable to those we have examined here, imperfections arising from the 
imputation may confound fine-mapping precision at some loci, and that robust inference will 
inevitably depend on integration of diverse sources of genetic, genomic and functional data.
The term “smoking gun” has often been used to describe the potential of functional coding 
variants to provide causal inference with respect to pathogenetic mechanisms37. This study 
provides a timely reminder that, even when a suspect with a smoking gun is found at the 
scene of a crime, it should not be assumed that they fired the fatal bullet.
ONLINE METHODS
Ethics statement
All human research was approved by the relevant institutional review boards, and conducted 
according to the Declaration of Helsinki. All participants provided written informed consent.
Derivation of significance thresholds
We considered five categories of annotation16 of variants on the exome array in order of 
decreasing effect on biological function: (1) PTVs (stop-gain and stop-loss, frameshift indel, 
donor and acceptor splice-site, and initiator codon variants, n1=8,388); (2) moderate-impact 
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variants (missense, in-frame indel, and splice region variants, n2=216,114); (3) low-impact 
variants (synonymous, 3′ and 5′ UTR, and upstream and downstream variants, n3=8,829); 
(4) other variants mapping to DNase I hypersensitive sites (DHS) in any of 217 cell types8 
(DHS, n4=3,561); and (5) other variants not mapping to DHS (n5=10,578). To account for 
the greater prior probability of causality for variants with greater effect on biological 
function, we determined a weighted Bonferroni-corrected significance threshold on the basis 
of reported enrichment16, denoted wi, in each annotation category, i: w1=165; w2=33; w3=3; 
w4=1.5; w5=0.5. For coding variants (annotation categories 1 and 2):
α =
0.05∑i = 1
2 niwi
∑i = 1
2 ni ∑i = 1
5 niwi
= 2.21 × 10−7 .
We note that this threshold is similar to a simple Bonferroni correction for the total number 
of coding variants on the array, which would yield:
α = 0.05224502 = 2.23 × 10
−7 .
For non-coding variants (annotation categories 3, 4 and 5) the weighted Bonferroni-
corrected significance threshold is:
α =
0.05∑i = 3
5 niwi
∑i = 3
5 ni ∑i = 1
5 niwi
= 9.45 × 10−9 .
DISCOVERY: Exome-array study-level analyses
Within each study, genotype calling and quality control were undertaken according to 
protocols developed by the UK Exome Chip Consortium or the CHARGE central calling 
effort38 (Supplementary Table 1). Within each study, variants were then excluded for the 
following reasons: (i) not mapping to autosomes or X chromosome; (ii) multi-allelic and/or 
insertion-deletion; (iii) monomorphic; (iv) call rate <99%; or (v) exact p<10−4 for deviation 
from Hardy-Weinberg equilibrium (autosomes only).
We tested association of T2D with each variant in a linear mixed model, implemented in 
RareMetalWorker17, using a genetic relationship matrix (GRM) to account for population 
structure and relatedness. For participants from family-based studies, known relationships 
were incorporated directly in the GRM. For founders and participants from population-based 
studies, the GRM was constructed from pair-wise identity by descent (IBD) estimates based 
on LD pruned (r2<0.05) autosomal variants with MAF≥1% (across cases and controls 
combined), after exclusion of those in high LD and complex regions39,40, and those mapping 
to established T2D loci. We considered additive, dominant, and recessive models for the 
effect of the minor allele, adjusted for age and sex (where appropriate) and additional study-
specific covariates (Supplementary Table 2). Analyses were also performed with and without 
adjustment for BMI (where available Supplementary Table 2).
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For single-variant association analyses, variants with minor allele count ≤10 in cases and 
controls combined were excluded. Association summary statistics for each analysis were 
corrected for residual inflation by means of genomic control41, calculated after excluding 
variants mapping to established T2D susceptibility loci. For gene-based analyses, we made 
no variant exclusions on the basis of minor allele count.
DISCOVERY: Exome-sequence analyses
We used summary statistics of T2D association from analyses conducted on 8,321 T2D 
cases and 8,421 controls across different ancestries, all genotyped using exome sequencing. 
Details of samples included, sequencing, and quality control are described elsewhere12,15 
(http://www.type2diabetesgenetics.org/). Samples were subdivided into 15 sub-groups 
according to ancestry and study of origin. Each sub-group was analysed independently, with 
sub-group specific principal components and genetic relatedness matrices. Association tests 
were performed with both a linear mixed model, as implemented in EMMAX42, using 
covariates for sequencing batch, and the Firth test, using covariates for principal components 
and sequencing batch. Related samples were excluded from the Firth analysis but 
maintained in the linear mixed model analysis. Variants were then filtered from each sub-
group analysis, according to call rate, differential case-control missing-ness, or deviation 
from Hardy-Weinberg equilibrium (as computed separately for each sub-group). Association 
statistics were then combined via a fixed-effects inverse-variance weighted meta-analysis, at 
both the level of ancestry as well as across all samples. P-values were taken from the linear 
mixed model analysis, while effect sizes estimates were taken from the Firth analysis. 
Analyses were performed with and without adjustment for BMI. From exome sequence 
summary statistics, we extracted variants passing quality control and present on the exome 
array.
DISCOVERY: GWAS analyses
The UK Biobank is a large detailed prospective study of more than 500,000 participants 
aged 40–69 years when recruited in 2006–201013. Prevalent T2D status was defined using 
self-reported medical history and medication in UK Biobank participants43. Participants 
were genotyped with the UK Biobank Axiom Array or UK BiLEVE Axiom Array, and 
quality control and population structure analyses were performed centrally at UK Biobank. 
We defined a subset of “white European” ancestry samples (n=120,286) as those who both 
self-identified as white British and were confirmed as ancestrally “Caucasian” from the first 
two axes of genetic variation from principal components analysis. Imputation was also 
performed centrally at UK Biobank for the autosomes only, up to a merged reference panel 
from the 1000 Genomes Project (multi-ethnic, phase 3, October 2014 release)44 and the 
UK10K Project9. We used SNPTESTv2.545 to test for association of T2D with each SNP in 
a logistic regression framework under an additive model, and after adjustment for age, sex, 
six axes of genetic variation, and genotyping array as covariates. Analyses were performed 
with and without adjustment for BMI, after removing related individuals.
GERA is a large multi-ethnic population-based cohort, created for investigating the genetic 
and environmental basis of age-related diseases [dbGaP phs000674.p1]. T2D status is based 
on ICD-9 codes in linked electronic medical health records, with all other participants 
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defined as controls. Participants have previously been genotyped using one of four custom 
arrays, which have been designed to maximise coverage of common and low-frequency 
variants in non-Hispanic white, East Asian, African American, and Latino ethnicities46,47. 
Methods for quality control have been described previously14. Each of the four genotyping 
arrays were imputed separately, up to the 1000 Genomes Project reference panel 
(autosomes, phase 3, October 2014 release; X chromosome, phase 1, March 2012 release) 
using IMPUTEv2.348,49. We used SNPTESTv2.545 to test for association of T2D with each 
SNP in a logistic regression framework under an additive model, and after adjustment for 
sex and nine axes of genetic variation from principal components analysis as covariates. 
BMI was not available for adjustment in GERA.
For UK Biobank and GERA, we extracted variants passing standard imputation quality 
control thresholds (IMPUTE info≥0.4)50 and present on the exome array. Association 
summary statistics under an additive model were corrected for residual inflation by means of 
genomic control41, calculated after excluding variants mapping to established T2D 
susceptibility loci: GERA (λ=1.097 for BMI unadjusted analysis) and UK Biobank 
(λ=1.043 for BMI unadjusted analysis, λ=1.056 for BMI adjusted analysis).
DISCOVERY: Single-variant meta-analysis
We aggregated association summary statistics under an additive model across studies, with 
and without adjustment for BMI, using METAL51: (i) effective sample size weighting of Z-
scores to obtain p-values; and (ii) inverse variance weighting of log-odds ratios. For exome-
array studies, allelic effect sizes and standard errors obtained from the RareMetalWorker 
linear mixed model were converted to the log-odds scale prior to meta-analysis to correct for 
case-control imbalance52.
The European-specific meta-analyses aggregated association summary statistics from a total 
of 48,286 cases and 250,671 controls from: (i) 33 exome-array studies of European ancestry; 
(ii) exome-array sequence from individuals of European ancestry; and (iii) GWAS from UK 
Biobank. Note that non-coding variants represented on the exome array were not available in 
exome sequence. The European-specific meta-analyses were corrected for residual inflation 
by means of genomic control41, calculated after excluding variants mapping to established 
T2D susceptibility loci: λ=1.091 for BMI unadjusted analysis and λ=1.080 for BMI 
adjusted analysis.
The trans-ethnic meta-analyses aggregated association summary statistics from a total of 
81,412 cases and 370,832 controls across all studies (51 exome array studies, exome 
sequence, and GWAS from UK Biobank and GERA), irrespective of ancestry. Note that 
non-coding variants represented on the exome array were not available in exome sequence. 
The trans-ethnic meta-analyses were corrected for residual inflation by means of genomic 
control41, calculated after excluding variants mapping to established T2D susceptibility loci: 
λ=1.073 for BMI unadjusted analysis and λ=1.068 for BMI adjusted analysis. 
Heterogeneity in allelic effect sizes between exome-array studies contributing to the trans-
ethnic meta-analysis was assessed by Cochran’s Q statistic53.
Mahajan et al. Page 12
Nat Genet. Author manuscript; available in PMC 2018 October 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
DISCOVERY: Detection of distinct association signals
Conditional analyses were undertaken to detect association signals by inclusion of index 
variants and/or tags for previously reported non-coding GWAS lead SNPs as covariates in 
the regression model at the study level. Within each exome-array study, approximate 
conditional analyses were undertaken under a linear mixed model using RareMetal17, which 
uses score statistics and the variance-covariance matrix from the RareMetalWorker single-
variant analysis to estimate the correlation in effect size estimates between variants due to 
LD. Study-level allelic effect sizes and standard errors obtained from the approximate 
conditional analyses were converted to the log-odds scale to correct for case-control 
imbalance52. Within each GWAS, exact conditional analyses were performed under a 
logistic regression model using SNPTESTv2.545. GWAS variants passing standard 
imputation quality control thresholds (IMPUTE info≥0.4)50 and present on the exome array 
were extracted for meta-analysis.
Association summary statistics were aggregated across studies, with and without adjustment 
for BMI, using METAL51: (i) effective sample size weighting of Z-scores to obtain p-values; 
and (ii) inverse variance weighting of log-odds ratios.
We defined novel loci as mapping >500kb from a previously reported lead GWAS SNP. We 
performed conditional analyses where a novel signal mapped close to a known GWAS locus, 
and the lead GWAS SNP at that locus is present (or tagged) on the exome array 
(Supplementary Table 5).
DISCOVERY: Non-additive association models
For exome-array studies only, we aggregated association summary statistics under recessive 
and dominant models across studies, with and without adjustment for BMI, using 
METAL51: (i) effective sample size weighting of Z-scores to obtain p-values; and (ii) inverse 
variance weighting of log-odds ratios. Allelic effect sizes and standard errors obtained from 
the RareMetalWorker linear mixed model were converted to the log-odds scale prior to 
meta-analysis to correct for case-control imbalance52. The European-specific meta-analyses 
aggregated association summary statistics from a total of 41,066 cases and 136,024 controls 
from 33 exome-array studies of European ancestry. The European-specific meta-analyses 
were corrected for residual inflation by means of genomic control41, calculated after 
excluding variants mapping to established T2D susceptibility loci: λ=1.076 and λ=1.083 for 
BMI unadjusted analysis, under recessive and dominant models respectively, and λ=1.081 
and λ=1.062 for BMI adjusted analysis, under recessive and dominant models respectively. 
The trans-ethnic meta-analyses aggregated association summary statistics from a total of 
58,425 cases and 188,032 controls across all exome-array studies, irrespective of ancestry. 
The trans-ethnic meta-analyses were corrected for residual inflation by means of genomic 
control41, calculated after excluding variants mapping to established T2D susceptibility loci: 
λ=1.041 and λ=1.071 for BMI unadjusted analysis, under recessive and dominant models 
respectively, and λ=1.031 and λ=1.063 for BMI adjusted analysis, under recessive and 
dominant models respectively.
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DISCOVERY: Gene-based meta-analyses
For exome-array studies only, we aggregated association summary statistics under an 
additive model across studies, with and without adjustment for BMI, using RareMetal17. 
This approach uses score statistics and the variance-covariance matrix from the 
RareMetalWorker single-variant analysis to estimate the correlation in effect size estimates 
between variants due to LD. We performed gene-based analyses using a burden test 
(assuming all variants have same direction of effect on T2D susceptibility) and SKAT 
(allowing variants to have different directions of effect on T2D susceptibility). We used two 
previously defined filters for annotation and MAF18 to define group files: (i) strict filter, 
including 44,666 variants; and (ii) broad filter, including all variants from the strict filter, and 
97,187 additional variants.
We assessed the contribution of each variant to gene-based signals by performing 
approximate conditional analyses. We repeated RareMetal analyses for the gene, excluding 
each variant in turn from the group file, and compared the strength of the association signal.
Fine-mapping of coding variant association signals with T2D susceptibility
We defined a locus as mapping 500kb up- and down-stream of each index coding variant 
(Supplementary Table 5), excluding the MHC. Our fine-mapping analyses aggregated 
association summary statistics from 24 GWAS incorporating 50,160 T2D cases and 465,272 
controls of European ancestry from the DIAGRAM Consortium (Supplementary Table 9). 
Each GWAS was imputed using miniMAC12 or IMPUTEv248,49 up to high-density 
reference panels: (i) 22 GWAS were imputed up to the Haplotype Reference Consortium20; 
(ii) the UK Biobank GWAS was imputed to a merged reference panel from the 1000 
Genomes Project (multi-ethnic, phase 3, October 2014 release)44 and the UK10K Project9; 
and (iii) the deCODE GWAS was imputed up to the deCODE Icelandic population-specific 
reference panel based on whole-genome sequence data19. Association with T2D 
susceptibility was tested for each remaining variant using logistic regression, adjusting for 
age, sex, and study-specific covariates, under an additive genetic model. Analyses were 
performed with and without adjustment for BMI. For each study, variants with minor allele 
count<5 (in cases and controls combined) or those with imputation quality r2-hat<0.3 
(miniMAC) or proper-info<0.4 (IMPUTE2) were removed. Association summary statistics 
for each analysis were corrected for residual inflation by means of genomic control41, 
calculated after excluding variants mapping to established T2D susceptibility loci.
We aggregated association summary statistics across studies, with and without adjustment 
for BMI, in a fixed-effects inverse variance weighted meta-analysis, using METAL51. The 
BMI unadjusted meta-analysis was corrected for residual inflation by means of genomic 
control (λ=1.012)41, calculated after excluding variants mapping to established T2D 
susceptibility loci. No adjustment was required for BMI adjusted meta-analysis (λ=0.994). 
From the meta-analysis, variants were extracted that were present on the HRC panel and 
reported in at least 50% of total effective sample size.
We included 37 of the 40 identified coding variants in fine-mapping analyses, excluding 
three that were not amenable to fine-mapping in the GWAS data sets: (i) the locus in the 
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major histocompatibility complex because of the extended and complex structure of LD 
across the region, which complicates fine-mapping efforts; (ii) the East Asian specific PAX4 
p.Arg190His (rs2233580) signal, since the variant was not present in European ancestry 
GWAS; and (iii) ZHX3 p.Asn310Ser (rs4077129) because the variant was only weakly 
associated with T2D in the GWAS data sets used for fine-mapping.
To delineate distinct association signals in four regions, we undertook approximate 
conditional analyses, implemented in GCTA54, to adjust for the index coding variants and 
non-coding lead GWAS SNPs: (i) RREB1 p. Asp1171Asn (rs9379084), p.Ser1499Tyr 
(rs35742417), and rs9505118; (ii) HNF1A p.Ile75Leu (rs1169288) and p.Ala146Val 
(rs1800574); (iii) GIPR p.Glu318Gln (rs1800437) and rs8108269; and (iv) HNF4A 
p.Thr139Ile (rs1800961) and rs4812831. We made use of summary statistics from the fixed-
effects meta-analyses (BMI unadjusted for RREB1, HNF1A, and HNF4A, and BMI adjusted 
for GIPR as this signal was only seen in BMI adjusted analysis) and genotype data from 
5,000 random individuals of European ancestry from the UK Biobank, as reference for LD 
between genetic variants across the region.
For each association signal, we first calculated an approximate Bayes’ factor55 in favour of 
association on the basis of allelic effect sizes and standard errors from the meta-analysis. 
Specifically, for the jth variant,
Λj =
V j
V j + ω
exp
ωβ j
2
2V j(V j + ω)
,
where βj and Vj denote the estimated allelic effect (log-OR) and corresponding variance 
from the meta-analysis. The parameter ω denotes the prior variance in allelic effects, taken 
here to be 0.0455.
We then calculated the posterior probability that the jth variant drives the association signal, 
given by
π j =
ρ jΛ j
∑kρkΛk
.
In this expression, ρj denotes the prior probability that the jth variant drives the association 
signal, and the summation in the denominator is over all variants across the locus. We 
considered two prior models: (i) functionally unweighted, for which ρj = 1 for all variants; 
and (ii) annotation informed, for which ρj is determined by the functional severity of the 
variant. For the annotation informed prior, we considered five categories of variation16, such 
that: (i) ρj = 165 for PTVs; (ii) ρj = 33 for moderate-impact variants; (iii) ρj = 3 for low-
impact variants; (iv) ρj = 1.5 for other variants mapping to DHS; and (v) ρj = 0.5 for all other 
variants.
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For each locus, the 99% credible set21 under each prior was then constructed by: (i) ranking 
all variants according to their posterior probability of driving the association signal; and (ii) 
including ranked variants until their cumulative posterior probability of driving the 
association attained or exceeded 0.99.
Functional impact of coding alleles
We used CADD34 to obtain scaled Combined Annotation Dependent Depletion score 
(CADD-score) for each of the 40 significantly associated coding variants. The CADD 
method objectively integrates a range of different annotation metrics into a single measure 
(CADD-score), providing an estimate of deleteriousness for all known variants and an 
overall rank for this metric across the genome. We obtained the estimates of the intolerance 
of a gene to harbouring loss-of-function variants (pLI) from the ExAC data set33. We used 
the Kolmogorov-Smirnov test to determine whether fine-mapping groups 1 and 2 have the 
same statistical distribution for each of these parameters.
T2D loci and physiological classification
To explore the different patterns of association between T2D and other anthropometric/
metabolic/endocrine traits and diseases, we performed hierarchical clustering analysis. We 
obtained association summary statistics for a range of metabolic traits and other outcomes 
for 94 coding and non-coding variants that were significantly associated with T2D through 
collaboration or by querying publically available GWAS meta-analysis datasets. The z-score 
(allelic effect/SE) was aligned to the T2D-risk allele. We obtained the distance matrix 
amongst z-score of the loci/traits using the Euclidean measure and performed clustering 
using the complete agglomeration method. Clustering was visualised by constructing a 
dendogram and heatmap.
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Figure 1. Posterior probabilities for coding variants across loci with annotation-informed priors
Fine-mapping of 37 distinct association signals was performed using European ancestry 
GWAS meta-analysis including 50,160 T2D cases and 465,272 controls. For each signal, we 
constructed a credible set of variants accounting for 99% of the posterior probability of 
driving the association, incorporating an “annotation informed” prior model of causality 
which “boosts” the posterior probability of driving the association signal that is attributed to 
coding variants. Each bar represents a signal with the total probability attributed to the 
coding variants within the 99% credible set plotted on the y-axis. When the probability (bar) 
is split across multiple coding variants (at least 0.05 probability attributed to a variant) at a 
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particular locus, these are indicated by blue, pink, yellow, and green colours. The combined 
probability of the remaining coding variants is highlighted in grey. RREB1(a): RREB1 p. 
Asp1171Asn; RREB1(b): RREB1 p.Ser1499Tyr; HNF1A(a): HNF1A p.Ala146Val; 
HNF1A(b): HNF1A p.Ile75Leu; PPIP5K2† : PPIP5K2 p.Ser1207Gly; MTMR3†: MTMR3 
p.Asn960Ser; IL17REL†: IL17REL p.Gly70Arg; NBEAL2†: NBEAL2 p.Arg511Gly, 
KIF9†: KIF9 p.Arg638Trp.
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Figure 2. Plot of measures of variant-specific and gene-specific features of distinct coding signals 
to access the functional impact of coding alleles
Each point represents a coding variant with the minor allele frequency plotted on the x-axis 
and the Combined Annotation Dependent Depletion score (CADD-score) plotted on the y-
axis. Size of each point varies with the measure of intolerance of the gene to loss of function 
variants (pLI) and the colour represents the fine-mapping group each variant is assigned to. 
Group 1: signal is driven by coding variant. Group 2: signal attributable to non-coding 
variants. Group 3: consistent with partial role for coding variants. Group 4: Unclassified 
category; includes PAX4, ZHX3, and signal at TCF19 within the MHC region where we did 
not perform fine-mapping. Inset: plot shows the distribution of CADD-score between 
different groups. The plot is a combination of violin plots and box plots; width of each violin 
indicates frequency at the corresponding CADD-score and box plots show the median and 
the 25% and 75% quantiles. P value indicates significance from two-sample Kolmogorov-
Smirnov test.
Mahajan et al. Page 31
Nat Genet. Author manuscript; available in PMC 2018 October 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mahajan et al. Page 32
Ta
bl
e 
1
Su
m
m
ar
y 
of
 d
isc
ov
er
y 
an
d 
fin
e-
m
ap
pi
ng
 a
na
ly
se
s o
f t
he
 4
0 
in
de
x
 c
o
di
ng
 v
ar
ia
nt
s a
ss
oc
ia
te
d 
w
ith
 T
2D
 (p
<
2.
2×
10
−
7 ).
D
isc
ov
er
y 
m
et
a-
an
al
ys
is 
us
in
g 
ex
om
e-
ar
ra
y 
co
m
po
ne
nt
: 8
1,
41
2 
T2
D
 ca
se
s a
nd
 3
70
,8
32
 co
nt
ro
ls 
fr
o
m
 d
iv
er
se
 a
n
ce
st
ri
es
Fi
ne
-m
ap
pi
ng
 m
et
a-
an
al
ys
is 
us
in
g 
G
W
A
S:
 5
0,
16
0 
T2
D
 ca
se
s a
nd
 4
65
,2
72
 co
nt
ro
ls 
fr
o
m
 E
ur
o
pe
an
 a
nc
es
tr
y
Lo
cu
s
In
de
x 
va
ri
an
t
rs
 ID
C
hr
Po
s
A
lle
le
s
R
A
F
BM
I u
na
dju
ste
d
BM
I a
dju
ste
d
R
A
F
O
R
L9
5
U
95
p-
v
a
lu
e
G
ro
u
p
R
/O
O
R
L9
5
U
95
p-
v
a
lu
e
O
R
L9
5
U
95
p-
v
a
lu
e
Pr
ev
io
us
ly
 re
po
rt
ed
 T
2D
 a
ss
oc
ia
te
d 
lo
ci
M
AC
F1
M
AC
F1
 
p.
M
et
14
24
Va
l
rs
22
96
17
2
1
39
,8
35
,8
17
G
/A
0.
19
3
1.
06
1.
05
1.
08
6.
7×
10
−
16
1.
04
1.
03
1.
06
5.
9×
10
−
8
0.
22
1.
08
1.
06
1.
1
1.
6×
10
−
15
3
GC
KR
GC
KR
 
p.
Pr
o4
46
Le
u
rs
12
60
32
6
2
27
,7
30
,9
40
C/
T
0.
63
0
1.
06
1.
05
1.
08
5.
3×
10
−
25
1.
06
1.
04
1.
07
3.
2×
10
−
18
0.
60
7
1.
05
1.
04
1.
07
9.
1×
10
−
10
1
TH
A
DA
TH
A
DA
 
p.
Cy
s8
45
Ty
r
rs
35
72
07
61
2
43
,5
19
,9
77
C/
T
0.
89
5
1.
08
1.
05
1.
1
4.
6×
10
−
15
1.
07
1.
05
1.
10
8.
3×
10
−
16
0.
88
1
1.
1
1.
07
1.
12
3.
4×
10
−
12
2
GR
B1
4
CO
BL
L1
 
p.
A
sn
90
1A
sp
rs
76
07
98
0
2
16
5,
55
1,
20
1
T/
C
0.
87
9
1.
08
1.
06
1.
11
8.
6×
10
−
20
1.
09
1.
07
1.
12
5.
0×
10
−
23
0.
87
1
1.
08
1.
06
1.
11
3.
6×
10
−
10
2
PP
A
RG
PP
A
RG
 
p.
Pr
o1
2A
la
rs
18
01
28
2
3
12
,3
93
,1
25
C/
G
0.
88
7
1.
09
1.
07
1.
11
1.
4×
10
−
17
1.
10
1.
07
1.
12
2.
7×
10
−
19
0.
87
6
1.
12
1.
09
1.
14
3.
7×
10
−
17
3
IG
F2
BP
2
SE
NP
2 
p.
Th
r2
91
Ly
s
rs
67
62
20
8
3
18
5,
33
1,
16
5
A
/C
0.
36
7
1.
03
1.
01
1.
04
1.
6×
10
−
6
1.
03
1.
02
1.
05
3.
0×
10
−
8
0.
33
9
1.
02
1.
01
1.
04
0.
01
2
W
FS
1
W
FS
1 
p.
Va
l3
33
Ile
rs
18
01
21
2
4
6,
30
2,
51
9
A
/G
0.
74
8
1.
07
1.
06
1.
09
1.
1×
10
−
24
1.
07
1.
05
1.
08
7.
1×
10
−
21
0.
70
3
1.
07
1.
05
1.
09
4.
1×
10
−
13
2
PA
M
-P
PI
P5
K2
PA
M
 
p.
A
sp
33
6G
ly
rs
35
65
86
96
5
10
2,
33
8,
81
1
G
/A
0.
04
5
1.
13
1.
10
1.
17
1.
2×
10
−
16
1.
13
1.
09
1.
17
7.
4×
10
−
15
0.
05
1
1.
17
1.
13
1.
22
2.
5×
10
−
17
1
RR
EB
1
RR
EB
1 
p.
A
sp
11
71
A
sn
rs
93
79
08
4
6
7,
23
1,
84
3
G
/A
0.
88
4
1.
08
1.
06
1.
11
1.
1×
10
−
13
1.
10
1.
07
1.
13
1.
5×
10
−
17
0.
88
8
1.
09
1.
06
1.
12
1.
1×
10
−
9
1
RR
EB
1 
p.
Se
r1
49
9T
yr
rs
35
74
24
17
6
7,
24
7,
34
4
C/
A
0.
83
6
1.
04
1.
03
1.
06
5.
5×
10
−
8
1.
04
1.
02
1.
06
2.
2×
10
−
7
0.
81
7
1.
04
1.
02
1.
07
0.
00
01
2
2
M
H
C
TC
F1
9 
p.
M
et
13
1V
al
rs
20
73
72
1
6
31
,1
29
,6
16
G
/A
0.
74
9
1.
04
1.
02
1.
05
1.
6×
10
−
10
1.
04
1.
02
1.
05
2.
3×
10
−
9
N
/A
N
/A
N
/A
N
/A
N
/A
N
/A
PA
X
4
PA
X
4 
p.
A
rg
19
0H
is
rs
22
33
58
0
7
12
7,
25
3,
55
0
T/
C
0.
02
9
1.
36
1.
25
1.
48
1.
8×
10
−
12
1.
38
1.
26
1.
51
4.
2×
10
−
13
0
N
/A
N
/A
N
/A
N
/A
N
/A
SL
C3
0A
8
SL
C3
0A
8 
p.
A
rg
27
6T
rp
rs
13
26
66
34
8
11
8,
18
4,
78
3
C/
T
0.
69
1
1.
09
1.
08
1.
11
1.
9×
10
−
47
1.
09
1.
08
1.
11
1.
3×
10
−
47
0.
68
3
1.
12
1.
1
1.
14
8.
2×
10
−
36
1
GP
SM
1
GP
SM
1 
p.
Se
r3
91
Le
u
rs
60
98
01
57
9
13
9,
23
5,
41
5
C/
T
0.
77
1
1.
06
1.
05
1.
08
3.
2×
10
−
16
1.
06
1.
05
1.
08
6.
6×
10
−
16
0.
75
6
1.
06
1.
04
1.
09
8.
3×
10
−
8
3
K
CN
J1
1-
AB
CC
8
K
CN
J1
1 
p.
Ly
s2
9G
lu
rs
52
19
11
17
,4
09
,5
72
T/
C
0.
36
4
1.
06
1.
05
1.
07
5.
7×
10
−
22
1.
07
1.
05
1.
08
1.
5×
10
−
22
0.
38
1
1.
07
1.
05
1.
09
8.
1×
10
−
16
1
CE
NT
D2
A
RA
P1
 
p.
G
ln
80
2G
lu
rs
56
20
08
89
11
72
,4
08
,0
55
G
/C
0.
73
3
1.
04
1.
02
1.
05
4.
8×
10
−
8
1.
05
1.
03
1.
06
5.
2×
10
−
10
0.
72
7
1.
05
1.
03
1.
07
2.
3×
10
−
8
2
K
LH
D
C5
M
RP
S3
5 
p.
G
ly
43
A
rg
rs
11
27
78
7
12
27
,8
67
,7
27
G
/A
0.
85
0
1.
06
1.
04
1.
08
1.
4×
10
−
11
1.
05
1.
03
1.
07
1.
5×
10
−
8
0.
84
2
1.
06
1.
04
1.
09
2.
2×
10
−
7
2
H
N
F1
A
H
N
F1
A
 
p.
Ile
75
Le
u
rs
11
69
28
8
12
12
1,
41
6,
65
0
C/
A
0.
32
3
1.
04
1.
03
1.
06
1.
1×
10
−
11
1.
04
1.
02
1.
06
1.
9×
10
−
10
0.
33
1.
05
1.
04
1.
07
4.
6×
10
−
9
1
H
N
F1
A
 
p.
A
la
14
6V
al
rs
18
00
57
4
12
12
1,
41
6,
86
4
T/
C
0.
02
9
1.
11
1.
06
1.
15
6.
1×
10
−
8
1.
10
1.
06
1.
15
1.
3×
10
−
7
0.
03
1.
16
1.
1
1.
21
5.
0×
10
−
9
1
M
PH
OS
PH
9
SB
NO
1 
p.
Se
r7
29
A
sn
rs
10
60
10
5
12
12
3,
80
6,
21
9
C/
T
0.
81
5
1.
04
1.
02
1.
06
5.
7×
10
−
7
1.
04
1.
02
1.
06
1.
1×
10
−
7
0.
78
7
1.
04
1.
02
1.
06
3.
6×
10
−
5
2
CI
LP
2
TM
6S
F2
 
p.
G
lu
16
7L
ys
rs
58
54
29
26
19
19
,3
79
,5
49
T/
C
0.
07
6
1.
07
1.
05
1.
10
4.
8×
10
−
12
1.
09
1.
06
1.
11
3.
4×
10
−
15
0.
07
6
1.
09
1.
05
1.
12
2.
0×
10
−
7
1
GI
PR
GI
PR
 
p.
G
lu
31
8G
ln
rs
18
00
43
7
19
46
,1
81
,3
92
C/
G
0.
20
0
1.
03
1.
02
1.
05
7.
1×
10
−
5
1.
06
1.
04
1.
07
6.
8×
10
−
12
0.
21
3
1.
09
1.
06
1.
12
4.
6×
10
−
9
1
H
N
F4
A
H
N
F4
A
 
p.
Th
r1
39
Ile
rs
18
00
96
1
20
43
,0
42
,3
64
T/
C
0.
03
2
1.
09
1.
05
1.
13
2.
6×
10
−
8
1.
10
1.
06
1.
14
5.
0×
10
−
8
0.
03
7
1.
17
1.
12
1.
22
1.
4×
10
−
12
1
Nat Genet. Author manuscript; available in PMC 2018 October 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mahajan et al. Page 33
D
isc
ov
er
y 
m
et
a-
an
al
ys
is 
us
in
g 
ex
om
e-
ar
ra
y 
co
m
po
ne
nt
: 8
1,
41
2 
T2
D
 ca
se
s a
nd
 3
70
,8
32
 co
nt
ro
ls 
fr
o
m
 d
iv
er
se
 a
n
ce
st
ri
es
Fi
ne
-m
ap
pi
ng
 m
et
a-
an
al
ys
is 
us
in
g 
G
W
A
S:
 5
0,
16
0 
T2
D
 ca
se
s a
nd
 4
65
,2
72
 co
nt
ro
ls 
fr
o
m
 E
ur
o
pe
an
 a
nc
es
tr
y
Lo
cu
s
In
de
x 
va
ri
an
t
rs
 ID
C
hr
Po
s
A
lle
le
s
R
A
F
BM
I u
na
dju
ste
d
BM
I a
dju
ste
d
R
A
F
O
R
L9
5
U
95
p-
v
a
lu
e
G
ro
u
p
R
/O
O
R
L9
5
U
95
p-
v
a
lu
e
O
R
L9
5
U
95
p-
v
a
lu
e
M
TM
R3
-A
SC
C2
A
SC
C2
 
p.
A
sp
40
7H
is
rs
28
26
5
22
30
,2
00
,7
61
C/
G
0.
92
5
1.
09
1.
06
1.
11
2.
1×
10
−
12
1.
09
1.
07
1.
12
4.
4×
10
−
14
0.
91
6
1.
1
1.
07
1.
14
9.
6×
10
−
11
3
N
ov
el
 T
2D
 a
ss
oc
ia
te
d 
lo
ci
FA
M
63
A
FA
M
63
A 
p.
Ty
r9
5A
sn
rs
14
03
86
49
8
1
15
0,
97
2,
95
9
A
/T
0.
98
8
1.
21
1.
14
1.
28
7.
5×
10
−
8
1.
19
1.
12
1.
26
6.
7×
10
−
7
0.
98
6
1.
15
1.
06
1.
25
0.
00
04
7
3
CE
P6
8
CE
P6
8 
p.
G
ly
74
Se
r
rs
75
72
85
7
2
65
,2
96
,7
98
G
/A
0.
84
6
1.
05
1.
04
1.
07
8.
3×
10
−
9
1.
05
1.
03
1.
07
6.
6×
10
−
7
0.
83
0
1.
06
1.
03
1.
08
6.
6×
10
−
7
2
K
IF
9
K
IF
9 
p.
A
rg
63
8T
rp
rs
22
76
85
3
3
47
,2
82
,3
03
A
/G
0.
58
8
1.
02
1.
01
1.
04
8.
0×
10
−
5
1.
03
1.
02
1.
05
5.
3×
10
−
8
0.
60
2
1.
04
1.
02
1.
05
2.
6×
10
−
5
3
A
N
K
H
A
N
K
H
 
p.
A
rg
18
7G
ln
rs
14
68
86
10
8
5
14
,7
51
,3
05
C/
T
0.
99
6
1.
29
1.
16
1.
45
1.
4×
10
−
7
1.
27
1.
13
1.
41
3.
5×
10
−
7
0.
99
5
1.
51
1.
29
1.
77
3.
5×
10
−
7
1
PO
C5
PO
C5
 
p.
H
is3
6A
rg
rs
23
07
11
1
5
75
,0
03
,6
78
T/
C
0.
56
2
1.
05
1.
04
1.
07
1.
6×
10
−
15
1.
03
1.
01
1.
04
2.
1×
10
−
5
0.
60
6
1.
06
1.
05
1.
08
1.
1×
10
−
12
1
LP
L
LP
L 
p.
Se
r4
74
*
rs
32
8
8
19
,8
19
,7
24
C/
G
0.
90
3
1.
05
1.
03
1.
08
6.
8×
10
−
9
1.
05
1.
03
1.
07
2.
3×
10
−
7
0.
90
1
1.
08
1.
05
1.
11
7.
1×
10
−
8
1
PL
CB
3†
PL
CB
3 
p.
Se
r7
78
Le
u
rs
35
16
97
99
11
64
,0
31
,2
41
T/
C
0.
07
1
1.
05
1.
02
1.
08
1.
3×
10
−
5
1.
06
1.
03
1.
09
1.
8×
10
−
7
0.
06
5
1.
07
1.
04
1.
11
3.
8×
10
−
5
1
TP
CN
2
TP
CN
2 
p.
Va
l2
19
Ile
rs
72
92
89
78
11
68
,8
31
,3
64
G
/A
0.
89
0
1.
05
1.
02
1.
07
5.
2×
10
−
7
1.
05
1.
03
1.
07
1.
8×
10
−
8
0.
84
7
1.
03
1.
00
1.
05
0.
04
2
2
W
SC
D2
W
SC
D2
 
p.
Th
r1
13
Ile
rs
37
64
00
2
12
10
8,
61
8,
63
0
C/
T
0.
71
9
1.
03
1.
02
1.
05
3.
3×
10
−
8
1.
03
1.
02
1.
05
1.
2×
10
−
7
0.
73
6
1.
05
1.
03
1.
07
8.
1×
10
−
7
1
ZZ
EF
1
ZZ
EF
1 
p.
Ile
40
2V
al
rs
78
18
31
17
3,
94
7,
64
4
C/
T
0.
42
2
1.
04
1.
03
1.
05
8.
3×
10
−
11
1.
03
1.
02
1.
05
1.
8×
10
−
7
0.
40
7
1.
04
1.
02
1.
05
2.
1×
10
−
5
2
M
LX
M
LX
 
p.
G
ln
13
9A
rg
rs
66
52
68
17
40
,7
22
,0
29
G
/A
0.
29
4
1.
04
1.
02
1.
05
2.
0×
10
−
8
1.
03
1.
02
1.
04
1.
1×
10
−
5
0.
28
0
1.
04
1.
02
1.
06
5.
2×
10
−
6
2
TT
LL
6
TT
LL
6 
p.
G
lu
71
2A
sp
rs
20
32
84
4
17
46
,8
47
,3
64
C/
A
0.
75
4
1.
04
1.
02
1.
06
1.
2×
10
−
7
1.
03
1.
01
1.
04
0.
00
09
8
0.
75
0
1.
04
1.
02
1.
06
9.
5×
10
−
5
3
C1
7o
rf5
8†
C1
7o
rf5
8 
p.
Ile
92
Va
l
rs
98
91
14
6
17
65
,9
88
,0
49
T/
C
0.
27
7
1.
04
1.
02
1.
06
1.
3×
10
−
7
1.
02
1.
00
1.
04
0.
00
05
8
0.
26
9
1.
05
1.
03
1.
07
1.
7×
10
−
7
2
ZH
X
3†
ZH
X
3 
p.
A
sn
31
0S
er
rs
17
26
55
13
20
39
,8
32
,6
28
C/
T
0.
21
1
1.
05
1.
03
1.
07
9.
2×
10
−
8
1.
04
1.
02
1.
05
2.
9×
10
−
6
0.
20
8
1.
02
1.
00
1.
04
0.
06
8
N
/A
PN
PL
A
3
PN
PL
A
3 
p.
Ile
14
8M
et
rs
73
84
09
22
44
,3
24
,7
27
G
/C
0.
23
9
1.
04
1.
03
1.
05
2.
1×
10
−
10
1.
05
1.
03
1.
06
2.
8×
10
−
11
0.
23
0
1.
05
1.
03
1.
07
5.
8×
10
−
6
1
PI
M
3
PI
M
3 
p.
Va
l3
00
A
la
rs
40
77
12
9
22
50
,3
56
,6
93
T/
C
0.
27
6
1.
04
1.
02
1.
05
1.
9×
10
−
7
1.
04
1.
02
1.
06
3.
5×
10
−
8
0.
28
0
1.
04
1.
02
1.
06
8.
7×
10
−
5
3
Ch
r: 
ch
ro
m
os
om
e.
 P
os
: P
os
iti
on
 b
u
ild
 3
7.
 R
A
F:
 ri
sk
 a
lle
le
 fr
eq
ue
nc
y.
 
R
: r
isk
 a
lle
le
. O
: o
th
er
 a
lle
le
. B
M
I: 
bo
dy
 m
as
s i
nd
ex
. 
O
R:
 o
dd
s r
at
io
. L
95
: l
ow
er
 9
5%
 co
nf
id
en
ce
 in
te
rv
al
. U
95
: u
pp
er
 9
5%
 co
nf
id
en
ce
 in
te
rv
al
. G
W
A
S:
 g
en
om
e 
w
id
e 
as
so
ci
at
io
n 
stu
di
es
.
† S
um
m
ar
y 
sta
tis
tic
s f
ro
m
 E
ur
op
ea
n 
an
ce
str
y 
sp
ec
ifi
c 
m
et
a-
an
al
ys
es
 o
f 4
8,
28
6 
ca
se
s a
nd
 2
50
,6
71
 co
nt
ro
ls.
 F
in
e-
m
ap
pi
ng
 g
ro
up
 1
: s
ig
na
l i
s d
riv
en
 b
y 
co
di
ng
 v
ar
ia
nt
, g
ro
up
 2
: s
ig
na
l a
ttr
ib
u
ta
bl
e 
to
 n
on
-c
od
in
g 
va
ria
nt
s, 
an
d 
gr
ou
p 
3:
 c
on
sis
te
nt
 w
ith
 p
ar
tia
l r
ol
e 
fo
r c
od
in
g 
va
ria
nt
s. 
p-
v
al
ue
s a
re
 b
as
ed
 o
n 
th
e 
m
et
a-
an
al
ys
es
 o
f d
isc
ov
er
y 
sta
ge
 a
nd
 fi
ne
-m
ap
pi
ng
 st
ud
ie
s a
s a
pp
ro
pr
ia
te
.
Nat Genet. Author manuscript; available in PMC 2018 October 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mahajan et al. Page 34
Ta
bl
e 
2
Po
st
er
io
r p
ro
ba
bi
lit
ie
s f
or
 c
od
in
g 
va
ria
nt
s w
ith
in
 9
9%
 cr
ed
ib
le
 se
t a
cr
os
s l
oc
i w
ith
 an
no
ta
tio
n-
in
fo
rm
ed
 an
d 
fu
nc
tio
na
lly
-u
nw
ei
gh
te
d 
pr
io
r b
as
ed
 o
n 
fin
e-
m
ap
pi
ng
 a
na
ly
sis
 p
er
fo
rm
ed
 u
sin
g 
50
,1
60
 T
2D
 ca
se
s a
nd
 4
65
,2
72
 co
nt
ro
ls 
of
 E
ur
op
ea
n 
an
ce
str
y.
Lo
cu
s
Va
ri
an
t
rs
 ID
C
hr
Po
sit
io
n
Po
st
er
io
r 
pr
o
ba
bi
lit
y
C
um
ul
at
iv
e 
po
st
er
io
r 
pr
o
ba
bi
lit
y 
at
tr
ib
u
te
d 
to
 c
od
in
g 
va
ri
an
ts
PP
A
a
iP
PA
PP
A
a
iP
PA
M
AC
F1
M
AC
F1
 
p.
Ile
39
Va
l
rs
16
82
60
69
1
39
,7
97
,0
55
0.
01
2
0.
24
0
0.
03
2
0.
62
8
M
AC
F1
 
p.
M
et
14
24
Va
l
rs
22
96
17
2
1
39
,8
35
,8
17
0.
01
1
0.
22
4
M
AC
F1
 
p.
Ly
s1
62
5A
sn
rs
41
27
08
07
1
39
,8
01
,8
15
0.
00
8
0.
16
3
FA
M
63
A
FA
M
63
A 
p.
Ty
r9
5A
sn
rs
14
03
86
49
8
1
15
0,
97
2,
95
9
0.
00
5
0.
12
9
0.
01
2
0.
30
3
GC
KR
GC
KR
 
p.
 P
ro
 4
46
Le
u
rs
12
60
32
6
2
27
,7
30
,9
40
0.
77
3
0.
99
5
0.
77
3
0.
99
5
TH
A
DA
TH
AD
A 
p.
C
ys
84
5T
yr
rs
35
72
07
61
2
43
,5
19
,9
77
<
0.
00
1
0.
01
1
0.
00
3
0.
12
0
TH
A
DA
 
p.
Th
r8
97
A
la
rs
75
78
59
7
2
43
,7
32
,8
23
0.
00
3
0.
10
7
CE
P6
8
CE
P6
8 
p.
G
ly
74
Se
r
rs
75
72
85
7
2
65
,2
96
,7
98
<
0.
00
1
0.
00
4
<
0.
00
1
0.
00
4
GR
B1
4
CO
BL
L1
 
p.
A
sn
90
1A
sp
rs
76
07
98
0
2
16
5,
55
1,
20
1
0.
00
6
0.
16
0
0.
00
6
0.
16
0
PP
A
RG
PP
A
RG
 
p.
Pr
o1
2A
la
rs
18
01
28
2
3
12
,3
93
,1
25
0.
02
3
0.
41
0
0.
02
4
0.
41
0
K
IF
9
SE
TD
2 
p.
Pr
o1
96
2L
ys
rs
40
82
15
5
3
47
,1
25
,3
85
0.
00
8
0.
17
1
0.
01
8
0.
38
4
N
BE
A
L2
 
p.
A
rg
51
1G
ly
rs
11
72
01
39
3
47
,0
36
,7
56
0.
00
5
0.
09
7
KI
F9
 
p.
A
rg
63
8T
rp
rs
22
76
85
3
3
47
,2
82
,3
03
0.
00
3
0.
05
9
IG
F2
BP
2
SE
NP
2 
p.
Th
r2
91
Ly
s
rs
67
62
20
8
3
18
5,
33
1,
16
5
<
0.
00
1
<
0.
00
1
<
0.
00
1
<
0.
00
1
W
FS
1
W
FS
1 
p.
Va
l3
33
Ile
rs
18
01
21
2
4
6,
30
2,
51
9
<
0.
00
1
0.
00
1
<
0.
00
1
0.
00
4
A
N
K
H
A
N
K
H
 
p.
A
rg
18
7G
ln
rs
14
68
86
10
8
5
14
,7
51
,3
05
0.
45
9
0.
97
2
0.
44
7
0.
97
2
PO
C5
PO
C5
 
p.
H
is3
6A
rg
rs
23
07
11
1
5
75
,0
03
,6
78
0.
69
7
0.
95
4
0.
70
2
0.
98
6
PA
M
-P
PI
P5
K2
PA
M
 
p.
A
sp
33
6G
ly
rs
35
65
86
96
5
10
2,
33
8,
81
1
0.
28
8
0.
88
5
0.
30
9
0.
94
7
PP
IP
5K
2 
p.
Se
r1
20
7G
ly
rs
36
04
65
91
5
10
2,
53
7,
28
5
0.
02
0
0.
06
3
RR
EB
1 
p.
A
sp
11
71
A
sn
RR
EB
1 
p.
A
sp
11
71
A
sn
rs
93
79
08
4
6
7,
23
1,
84
3
0.
92
0
0.
99
7
0.
92
0
0.
99
7
RR
EB
1 
p.
Se
r1
49
9T
yr
RR
EB
1 
p.
Se
r1
49
9T
yr
rs
35
74
24
17
6
7,
24
7,
34
4
<
0.
00
1
0.
01
3
0.
00
5
0.
11
1
LP
L
LP
L 
p.
Se
r4
74
*
rs
32
8
8
19
,8
19
,7
24
0.
02
3
0.
83
2
0.
02
3
0.
83
2
SL
C3
0A
8
SL
C3
0A
8 
p.
A
rg
27
6T
rp
rs
13
26
66
34
8
11
8,
18
4,
78
3
0.
29
5
0.
82
3
0.
29
5
0.
82
3
GP
SM
1
GP
SM
1 
p.
Se
r3
91
Le
u
rs
60
98
01
57
9
13
9,
23
5,
41
5
0.
03
1
0.
55
7
0.
03
1
0.
55
7
K
CN
J1
1-
AB
CC
8
K
CN
J1
1 
p.
Va
l2
50
Ile
rs
52
15
11
17
,4
08
,6
30
0.
20
8
0.
41
2
0.
48
1
0.
95
1
Nat Genet. Author manuscript; available in PMC 2018 October 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mahajan et al. Page 35
Lo
cu
s
Va
ri
an
t
rs
 ID
C
hr
Po
sit
io
n
Po
st
er
io
r 
pr
o
ba
bi
lit
y
C
um
ul
at
iv
e 
po
st
er
io
r 
pr
o
ba
bi
lit
y 
at
tr
ib
u
te
d 
to
 c
od
in
g 
va
ri
an
ts
PP
A
a
iP
PA
PP
A
a
iP
PA
KC
N
J1
1 p
.L
ys
29
G
lu
rs
52
19
11
17
,4
09
,5
72
0.
19
0
0.
37
6
A
BC
C8
 
p.
A
la
13
69
Se
r
rs
75
71
10
11
17
,4
18
,4
77
0.
08
3
0.
16
3
PL
CB
3
PL
CB
3 
p.
Se
r7
78
Le
u
rs
35
16
97
99
11
64
,0
31
,2
41
0.
11
3
0.
72
0
0.
13
0
0.
83
0
TP
CN
2
TP
CN
2 
p.
Va
l2
19
Ile
rs
72
92
89
78
11
68
,8
31
,3
64
<
0.
00
1
0.
00
4
0.
00
6
0.
14
0
CE
NT
D2
A
RA
P1
 
p.
G
ln
80
2G
lu
rs
56
20
08
89
11
72
,4
08
,0
55
<
0.
00
1
<
0.
00
1
<
0.
00
1
<
0.
00
1
K
LH
D
C5
M
RP
S3
5 
p.
G
ly
43
A
rg
rs
11
27
78
7
12
27
,8
67
,7
27
<
0.
00
1
<
0.
00
1
<
0.
00
1
<
0.
00
1
W
SC
D2
W
SC
D2
 
p.
Th
r1
13
Ile
rs
37
64
00
2
12
10
8,
61
8,
63
0
0.
28
1
0.
95
5
0.
28
2
0.
95
8
H
N
F1
A
 
p.
Ile
75
Le
u
H
N
F1
A
_
G
ly
22
6A
la
rs
56
34
85
80
12
12
1,
43
2,
11
7
0.
35
8
0.
89
4
0.
35
8
0.
89
4
H
N
F1
A 
p.
Ile
75
Le
u
rs
11
69
28
8
12
12
1,
41
6,
65
0
<
0.
00
1
<
0.
00
1
H
N
F1
A
 
p.
A
la
14
6V
al
H
N
F1
A
 
p.
A
la
14
6V
al
rs
18
00
57
4
12
12
1,
41
6,
86
4
0.
26
9
0.
86
7
0.
28
0
0.
90
2
M
PH
OS
PH
9
SB
NO
1 
p.
Se
r7
29
A
sn
rs
10
60
10
5
12
12
3,
80
6,
21
9
0.
00
2
0.
05
4
0.
00
2
0.
05
7
ZZ
EF
1
ZZ
EF
1 
p.
Ile
40
2V
al
rs
78
18
31
17
3,
94
7,
64
4
<
0.
00
1
0.
00
1
<
0.
00
1
0.
01
8
M
LX
M
LX
 
p.
G
ln
13
9A
rg
rs
66
52
68
17
40
,7
22
,0
29
0.
00
2
0.
03
8
0.
00
2
0.
03
9
TT
LL
6
TT
LL
6 
p.
G
lu
71
2A
sp
rs
20
32
84
4
17
46
,8
47
,3
64
<
0.
00
1
<
0.
00
1
0.
01
6
0.
30
5
CA
LC
OC
O2
 
p.
Pr
o3
47
A
la
rs
10
27
8
17
46
,9
39
,6
58
0.
01
00
0.
18
7
SN
F8
 
p.
A
rg
15
5H
is
rs
57
90
10
04
17
47
,0
11
,8
97
0.
00
5
0.
09
2
C1
7o
rf5
8
C1
7o
rf5
8 
p.
Ile
92
Va
l
rs
98
91
14
6
17
65
,9
88
,0
49
<
0.
00
1
0.
00
9
<
0.
00
1
0.
00
9
CI
LP
2
TM
6S
F2
 
p.
G
lu
16
7L
ys
rs
58
54
29
26
19
19
,3
79
,5
49
0.
21
1
0.
73
2
0.
26
3
0.
91
3
TM
6S
F2
 
p.
Le
u1
56
Pr
o
rs
18
74
29
06
4
19
19
,3
80
,5
13
0.
04
9
0.
17
2
GI
PR
GI
PR
 
p.
G
lu
31
8G
ln
rs
18
00
43
7
19
46
,1
81
,3
92
0.
16
9
0.
90
1
0.
16
9
0.
90
1
ZH
X
3
ZH
X
3 
p.
A
sn
31
0S
er
rs
17
26
55
13
20
39
,8
32
,6
28
<
0.
00
1
0.
00
3
0.
00
3
0.
11
0
H
N
F4
A
H
N
F4
A
 
p.
Th
r1
39
Ile
rs
18
00
96
1
20
43
,0
42
,3
64
1.
00
0
1.
00
0
1.
00
1.
00
0
M
TM
R3
-A
SC
C2
AS
CC
2 
p.
A
sp
40
7H
is
rs
28
26
5
22
30
,2
00
,7
61
0.
01
1
0.
19
2
0.
02
8
0.
48
1
A
SC
C2
 
p.
Pr
o4
23
Se
r
rs
36
57
1
22
30
,2
00
,7
13
0.
00
7
0.
11
6
A
SC
C2
 
p.
Va
l1
23
Ile
rs
11
54
97
95
22
30
,2
21
,1
20
0.
00
6
0.
10
7
M
TM
R3
 
p.
A
sn
96
0S
er
rs
41
27
88
53
22
30
,4
16
,5
27
0.
00
4
0.
06
5
PN
PL
A
3
PN
PL
A
3 
p.
Ile
14
8M
et
rs
73
84
09
22
44
,3
24
,7
27
0.
11
2
0.
69
1
0.
13
0
0.
80
6
PA
RV
B 
p.
Tr
p3
7A
rg
rs
10
07
86
3
22
44
,3
95
,4
51
0.
01
7
0.
10
3
Nat Genet. Author manuscript; available in PMC 2018 October 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mahajan et al. Page 36
Lo
cu
s
Va
ri
an
t
rs
 ID
C
hr
Po
sit
io
n
Po
st
er
io
r 
pr
o
ba
bi
lit
y
C
um
ul
at
iv
e 
po
st
er
io
r 
pr
o
ba
bi
lit
y 
at
tr
ib
u
te
d 
to
 c
od
in
g 
va
ri
an
ts
PP
A
a
iP
PA
PP
A
a
iP
PA
PI
M
3
IL
17
RE
L 
p.
Le
u3
33
Pr
o
rs
57
71
06
9
22
50
,4
35
,4
80
0.
04
1
0.
41
9
0.
04
7
0.
47
5
IL
17
RE
L 
p.
G
ly
70
A
rg
rs
96
17
09
0
22
50
,4
39
,1
94
0.
00
5
0.
05
4
PI
M
3 
p.
Va
l3
00
A
la
rs
40
77
12
9
22
50
,3
56
,6
93
<
0.
00
1
0.
00
2
Ch
r: 
ch
ro
m
os
om
e.
 P
os
: P
os
iti
on
 b
u
ild
 3
7.
 P
PA
: f
un
ct
io
na
lly
-u
nw
ei
gh
te
d 
pr
io
r; 
ai
PP
A
: a
nn
ot
at
io
n 
in
fo
rm
ed
 p
rio
r. 
In
de
x
 c
o
di
ng
 v
ar
ia
nt
s a
re
 h
ig
hl
ig
ht
ed
 in
 b
ol
d.
Nat Genet. Author manuscript; available in PMC 2018 October 09.
